Get the Stockscreener App
2.29
0.44%
0.01
After Hours:
2.30
0.010
+0.44%
Invivyd Inc stock is traded at $2.29, with a volume of 2.36M.
It is up +0.44% in the last 24 hours and down -9.49% over the past month.
Invivyd Inc is a clinical-stage biopharmaceutical company focused on the discovery, development, and commercialization of antibody-based solutions for infectious diseases with pandemic potential. The company is developing antibodies to transcend the limits of naturally occurring immunity and provide superior protection from viral diseases, beginning with COVID-19. The company's product candidates are; ADG20 developed for the treatment and prevention of coronavirus disease, and VYD222, a monoclonal antibody candidate engineered, optimizing for potency and breadth of coverage, as well as providing a higher probability of retaining its utility for a longer duration in an evolving viral landscape.
See More
Previous Close:
$2.28
Open:
$2.28
24h Volume:
2.36M
Relative Volume:
0.35
Market Cap:
$634.48M
Revenue:
-
Net Income/Loss:
$-225.14M
P/E Ratio:
-1.1684
EPS:
-1.96
Net Cash Flow:
$-192.27M
1W Performance:
-3.78%
1M Performance:
-9.49%
6M Performance:
+205.74%
1Y Performance:
+415.07%
1-Day Range:
$2.28
$2.41
1-Week Range:
$2.18
$2.435
52-Week Range:
$0.3546
$3.0699
Invivyd Inc Stock (IVVD) Company Profile
Name
Invivyd Inc
Sector
Industry
Phone
(781) 819-0080
Address
209 CHURCH STREET, NEW HAVEN
Compare IVVD with other stocks
| Stocks | Price | Market Cap | Revenue | Net Income | Cash Flow | EPS |
|---|---|---|---|---|---|---|
IVVD
Invivyd Inc
|
2.29 | 631.71M | 0 | -225.14M | -192.27M | -1.96 |
|
VRTX
Vertex Pharmaceuticals Inc
|
447.38 | 114.05B | 11.74B | 3.68B | 3.34B | 14.19 |
|
REGN
Regeneron Pharmaceuticals Inc
|
748.71 | 78.80B | 14.25B | 4.58B | 3.88B | 41.77 |
|
ALNY
Alnylam Pharmaceuticals Inc
|
396.04 | 51.80B | 3.21B | 43.57M | 221.36M | 0.2405 |
|
ARGX
Argen X Se Adr
|
847.05 | 53.08B | 3.06B | 1.28B | 447.35M | 19.67 |
|
INSM
Insmed Inc
|
166.55 | 42.33B | 447.02M | -1.18B | -906.14M | -6.1812 |
Invivyd Inc Stock (IVVD) Upgrades & Downgrades
| Date | Action | Analyst | Rating Change |
|---|---|---|---|
| Nov-25-25 | Downgrade | D. Boral Capital | Buy → Hold |
| Oct-06-25 | Initiated | Cantor Fitzgerald | Overweight |
| Apr-05-24 | Upgrade | Guggenheim | Neutral → Buy |
| Mar-26-24 | Upgrade | Morgan Stanley | Equal-Weight → Overweight |
| Dec-19-23 | Upgrade | Morgan Stanley | Underweight → Equal-Weight |
| May-01-23 | Initiated | H.C. Wainwright | Buy |
View All
Invivyd Inc Stock (IVVD) Latest News
What sentiment indicators say about Invivyd Inc. stock2025 Sector Review & Smart Money Movement Tracker - Улправда
Is Invivyd Inc. stock a good choice for value investors2025 Historical Comparison & Precise Entry and Exit Recommendations - Улправда
Invivyd, Inc. (IVVD): Advancing RSV Antibody VBY329 Amid Analyst Downgrade - Yahoo! Finance Canada
Invivyd, Inc. (IVVD): Advancing RSV antibody VBY329 amid analyst downgrade - MSN
Exploring Three High Growth Tech Stocks In The US Market - simplywall.st
Invivyd Nominates RSV Antibody, Spurs Market Interest - StocksToTrade
Invivyd (NASDAQ:IVVD) Stock Price Up 6.1%Still a Buy? - MarketBeat
Invivyd, RF Industries, and DLocal Lead Impressive Stock Returns in Recent Months - Markets Mojo
Maverick Capital Ltd. Has $7.31 Million Position in Invivyd, Inc. $IVVD - MarketBeat
Invivyd (NASDAQ:IVVD) Trading Up 7%Still a Buy? - MarketBeat
Is Invivyd (IVVD) Using RSV Prophylaxis To Redefine Its Post‑COVID Strategy? - simplywall.st
Invivyd (IVVD) Is Down 8.6% After Advancing VBY329 For Pediatric RSV PreventionWhat's Changed - Yahoo Finance
What Analysts Think Is Changing The Story For Invivyd Now - Yahoo Finance
Will Invivyd Inc. stock deliver consistent dividendsWeekly Trend Recap & Daily Oversold Bounce Ideas - Newser
Invivyd (NASDAQ:IVVD) Shares Down 3.8%Here's Why - MarketBeat
Invivyd (NASDAQ:IVVD) Shares Gap UpWhat's Next? - MarketBeat
What catalysts could drive Invivyd Inc. stock higherQuarterly Performance Summary & Weekly Watchlist for Consistent Profits - Newser
How Invivyd Inc. stock compares to industry benchmarksJuly 2025 Breakouts & AI Enhanced Trade Execution Alerts - Newser
A Look at Invivyd (IVVD) Valuation After Advancing VBY329 RSV Antibody Candidate into Preclinical Development - Yahoo Finance
Optimistic Investors Push Invivyd, Inc. (NASDAQ:IVVD) Shares Up 27% But Growth Is Lacking - simplywall.st
Is Invivyd Inc. stock supported by strong fundamentalsTrade Analysis Summary & Weekly Sector Rotation Insights - moha.gov.vn
Could Invivyd's (IVVD) Pipeline Expansion Reveal a Shift in Its Long-Term Competitive Strategy? - simplywall.st
Invivyd Appoints New Director Amid Nasdaq Compliance - MSN
Invivyd Reports Third Quarter 2025 Financial Results and Recent Business Highlights - ADVFN
Invivyd Raises $117.2 Million in Public Offering - MSN
Invivyd, Inc. (NASDAQ:IVVD) Given Average Recommendation of "Hold" by Brokerages - MarketBeat
D. Boral Capital Downgrades Invivyd (IVVD) - MSN
Invivyd (NASDAQ:IVVD) Earns Hold Rating from D. Boral Capital - MarketBeat
This Coinbase Analyst Is No Longer Bullish; Here Are Top 5 Downgrades For Tuesday - Benzinga
Invivyd (IVVD) Downgraded to Hold by D. Boral Capital | IVVD Sto - GuruFocus
Invivyd to Participate at the 8th Annual Evercore Healthcare Conference - The Globe and Mail
Kevin McLaughlin Buys Handful Of Shares In Invivyd - simplywall.st
Invivyd (Nasdaq: IVVD) to Join 8th Annual Evercore Healthcare Conference Fireside Chat - Stock Titan
Invivyd nominates promising RSV antibody candidate for infants By Investing.com - Investing.com Australia
Invivyd Unveils Promising RSV Antibody Candidate - TipRanks
New Haven-based biotech firm nets $117M from public offering - Hartford Business Journal
Invivyd Selects Antibody Candidate for Respiratory Syncytial Virus Prevention - MarketScreener
Invivyd nominates promising RSV antibody candidate for infants - Investing.com
Invivyd Announces Selection of Potential Best-In-Class RSV Antibody Candidate VBY329; Targeting 2H 2026 IND Readiness - The Manila Times
Invivyd, Inc. Advances VBY329 as Promising Monoclonal Antibody Candidate for RSV Prevention in Infants and Children - Quiver Quantitative
[8-K] Invivyd, Inc. Reports Material Event | IVVD SEC FilingForm 8-K - Stock Titan
Invivyd (Nasdaq: IVVD) picks RSV antibody VBY329, 1.5-fold potency, IND in 2026 - Stock Titan
Four companies raise nearly $950M in follow-ons: Public Equity Report - BioCentury
What is the fair value of Invivyd Inc. stock nowIPO Watch & AI Driven Stock Reports - newser.com
Invivyd Stock Hits 19-Month High As Public Offering Lands Days After Point72, Janus Henderson Reveal Big Stakes - MSN
Invivyd Director Kevin F. McLaughlin Acquires 50,000 Shares - TradingView
Dir McLaughlin Buys 50,000 ($125K) Of Invivyd Inc [IVVD] - TradingView
[Form 4] Invivyd, Inc. Insider Trading Activity - Stock Titan
Candlestick signals on Invivyd Inc. stock todayTrade Exit Summary & Consistent Return Investment Signals - newser.com
Can Invivyd Inc. stock deliver surprise earnings beatQuarterly Risk Review & Daily Chart Pattern Signal Reports - newser.com
Invivyd announces proposed public offering of common stock - MSN
Invivyd Inc Stock (IVVD) Financials Data
Revenue
Net Income
Cash Flow
EPS
0.31%
0.33%
Open in Yahoo
|
Open in Google
|
Open in Finviz
|
Open in MarketWatch
|
Open in EDGAR
|
Open in Reuters
Cap:
|
Volume (24h):